AnaptysBio Inc (ANAB) Receives $122.36 Consensus PT from Brokerages

Shares of AnaptysBio Inc (NASDAQ:ANAB) have received a consensus recommendation of “Buy” from the thirteen analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $122.36.

Several brokerages recently commented on ANAB. Zacks Investment Research downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $140.00 price target on shares of AnaptysBio in a report on Tuesday. Guggenheim assumed coverage on shares of AnaptysBio in a report on Friday, February 22nd. They issued a “buy” rating and a $135.00 price target on the stock. Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a report on Friday, March 1st. Finally, HC Wainwright assumed coverage on shares of AnaptysBio in a report on Thursday, December 20th. They issued a “buy” rating and a $126.00 price target on the stock.

In other news, insider Marco Londei sold 19,075 shares of the business’s stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $69.88, for a total transaction of $1,332,961.00. Following the sale, the insider now owns 22,377 shares in the company, valued at approximately $1,563,704.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Hamza Suria sold 40,000 shares of the business’s stock in a transaction on Monday, January 14th. The shares were sold at an average price of $70.79, for a total transaction of $2,831,600.00. Following the sale, the chief executive officer now owns 70,064 shares in the company, valued at approximately $4,959,830.56. The disclosure for this sale can be found here. Insiders own 20.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. United Services Automobile Association boosted its holdings in shares of AnaptysBio by 6.2% during the 4th quarter. United Services Automobile Association now owns 4,647 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 271 shares in the last quarter. Quantamental Technologies LLC bought a new stake in shares of AnaptysBio during the 4th quarter valued at $38,000. State Board of Administration of Florida Retirement System boosted its holdings in shares of AnaptysBio by 7.2% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 10,007 shares of the biotechnology company’s stock valued at $638,000 after buying an additional 674 shares in the last quarter. Swiss National Bank boosted its holdings in shares of AnaptysBio by 3.5% during the 3rd quarter. Swiss National Bank now owns 29,700 shares of the biotechnology company’s stock valued at $2,963,000 after buying an additional 1,000 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in shares of AnaptysBio by 1.0% during the 4th quarter. Brown Advisory Inc. now owns 115,400 shares of the biotechnology company’s stock valued at $7,361,000 after buying an additional 1,114 shares in the last quarter.

Shares of NASDAQ ANAB traded up $3.96 during mid-day trading on Wednesday, hitting $73.05. The stock had a trading volume of 301,474 shares, compared to its average volume of 277,520. AnaptysBio has a 1 year low of $54.26 and a 1 year high of $110.00. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -29.22 and a beta of 2.30.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, February 28th. The biotechnology company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.27. As a group, equities analysts predict that AnaptysBio will post -3.24 EPS for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Featured Article: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.